Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.44 |
| ▸ | TFPI | P10646 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12038534 | 0.84 | KISS1R (0.46) | KISS1RTFPIBACE1 | |
| SCHEMBL12038559 | 0.83 | NPY2R (0.59) | TFPI | |
| SCHEMBL12038572 | 0.82 | NPY2R (0.52) | TFPIGLP1R | |
| SCHEMBL12038609 | 0.81 | KISS1R (0.40) | KISS1RBACE1 | |
| SCHEMBL16589778 | 0.81 | VIPR1 (0.51) | VIPR1TFPIVIPR2GLP1R | |
| SCHEMBL12038621 | 0.81 | NPY2R (0.59) | TFPI | |
| SCHEMBL12038668 | 0.80 | NPY2R (0.59) | TFPI | |
| SCHEMBL29972087 | 0.80 | KISS1R (0.56) | KISS1RGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL25544142 | 0.79 | NPY2R (0.59) | TFPI | |
| SCHEMBL15791193 | 0.77 | TFPI (0.56) | KISS1RF2VIPR1TFPIVIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783578-B2 | Immunosuppression modulating compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-10-10 | — | — | US | disclosed |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-8907053-B2 | Immunosuppression modulating compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20110318373-A1 | IMMUNOSUPPRESSION MODULATING COMPOUNDS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318373-A1 | IMMUNOSUPPRESSION MODULATING COMPOUNDS | CD274, PDCD1, PDCD1LG2 | KISS1R 2026/4885GRIN2D 4109/4885GRIN3B 3129/4885 |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | CD274, PDCD1, PDCD1LG2 | KISS1R 2012/4885GRIN2D 3993/4885GRIN3B 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.